This bill allows physicians in New Jersey to perform certain types of stem cell therapy that have not yet received approval from the United States Food and Drug Administration (FDA), specifically for treatments related to orthopedics, wound care, or pain management. The bill emphasizes the ethical sourcing of stem cells, prohibiting the use of cells derived from aborted fetuses and mandating that any stem cells used must be obtained from FDA-registered facilities that meet specific certification or accreditation standards. Additionally, the bill requires that these stem cells contain viable cells upon post-thaw analysis and mandates that physicians provide patients with a clear notice regarding the unapproved status of the therapies in advertisements.

To ensure patient safety and informed consent, the bill stipulates that physicians must obtain a signed consent form from patients before administering stem cell therapy, detailing the nature of the treatment, potential risks, and the recommendation to consult with a primary care provider. Violations of the bill's provisions may lead to disciplinary action by the State Board of Medical Examiners, and serious offenses, such as using cells derived from aborted fetuses, are classified as a third-degree crime. Certain exemptions are provided for physicians who have FDA approval for investigational drugs or who work under accredited institutions.